Propelling healthcare with advanced therapy medicinal products: a policy discussion

D Horgan, A Metspalu, MC Ouillade, D Athanasiou… - Biomedicine …, 2020 - karger.com
Recent advances in biomedicine are opening the door to new approaches, and treatment
and prevention are being transformed by novel medicines based on genetic engineering …

Challenges with advanced therapy medicinal products and how to meet them

Nature reviews Drug discovery, 2010 - nature.com
Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal
products, somatic cell therapy medicinal products and tissue-engineered products, are at the …

(Committee for Advanced Therapies (CAT), CAT Scientific Secretariat), Challenges with advanced therapy medicinal products and how to meet them

CK Schneider, B Flamion, I Haunerova… - Nature Reviews. Drug …, 2010 - ikee.lib.auth.gr
Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal
products, somatic cell therapy medicinal products and tissue-engineered products, are at the …

[HTML][HTML] Advanced therapy medicinal products' translation in Europe: a developers' perspective

M Pizevska, J Kaeda, E Fritsche, H Elazaly… - Frontiers in …, 2022 - frontiersin.org
Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-
engineered therapies have demonstrated enormous therapeutic benefits. However, their …

Payer and implementation challenges with advanced therapy medicinal products (ATMPs)

J Spoors, A Miners, J Cairns, D Palnoch… - BioDrugs, 2021 - Springer
Advanced therapy medicinal products (ATMPs) are a dynamic and current topic for
healthcare systems, with new products progressing to market at an increasing rate. ATMPs …

[HTML][HTML] Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review

L Aguilera-Cobos, MP Rosario-Lozano, A Ponce-Polo… - Health policy, 2022 - Elsevier
Advanced therapy medicinal products (ATMPs) are a fast-growing field of medicine with
wide potential application. Nevertheless, so far, only 19 have obtained European Union …

[HTML][HTML] Perspectives, expectations, and concerns of European patient advocates on advanced therapy medicinal products

S Benvenuti, CM Wang, S Borroni - Frontiers in Medicine, 2021 - frontiersin.org
This paper presents the results of a qualitative study based on semi-structured interviews of
10 expert patient advocates on several different issues around Advanced Therapy Medicinal …

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

V Ronco, M Dilecce, E Lanati… - … Policy and Practice, 2021 - Taylor & Francis
Background Advanced therapy medicinal products (ATMPs) represent an important
cornerstone for innovation in healthcare. However, uncertainty on the value, the high …

Advanced therapy medicinal products: current and future perspectives

E Hanna, C Rémuzat, P Auquier, M Toumi - Journal of market access & …, 2016 - mdpi.com
Background: Advanced therapy medicinal products (ATMPs) are innovative therapies that
encompass gene therapy, somatic cell therapy, and tissue-engineered products. These …

[HTML][HTML] Market access of atmps: overview and expected challenges

E Hanna, F Tavella, C Rémuzat, P Auquier… - Value in …, 2015 - valueinhealthjournal.com
Objectives Advanced therapy medicinal products (ATMPs) are a class of innovative and
regenerative therapies. As of May 2015, only 5 ATMPs were granted a marketing …